However, while prostate imaging by PSMA PET/CT detects sites of prostate cancer recurrence inside and outside of the treatment area at lower PSA levels, one must take into consideration the known “Will Rogers effect” [10], potentially triggering earlier treatment initiation and raising real-life questions regarding the clinical impact of such findings on its impact on disease-specific and overall survival rather than other disease pathway timepoints [11]. The gene discussed is KLK3; the disease is Familial prostate cancer.